Tony Locantro checks out Tryptamine Therapeutics and its advancements as a pioneer of the fast-emerging psychedelic sector.

“The world needs to see efficacy data, not just trendy buzzwords,” he says. Tryptamine’s drug of choice – so to speak – is a synthetic version of psilocybin, the active ingredient in ...

Tryptamine Therapeutics (ASX:TYP) has appointed Herwig Janssen as non-executive chairman effective today and he brings ...

Followed categories will be added to My News. Tryptamine is focused on using psilocybin to treat difficult mental health and neurological conditions In league with Swinburne University ...

Special Report: Psychedelic drug developer Tryptamine Therapeutics has appointed a global pharmaceutical leader as its new chairman and made targeted board changes to strengthen leadership ahead ...